Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714665 | 0.90 | HDAC6 (0.35) | HDAC6HDAC1HDAC2L3MBTL1ALDH1A1 | |
| SCHEMBL28234844 | 0.86 | HDAC6 (0.33) | HDAC6HDAC1HDAC2L3MBTL1DPP4 | |
| SCHEMBL26284156 | 0.85 | HDAC6 (0.31) | HDAC6 | |
| SCHEMBL28790852 | 0.84 | HDAC6 (0.32) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL5754316 | 0.84 | HDAC6 (0.35) | HDAC6HDAC1HDAC2L3MBTL1ALDH1A1 | |
| SCHEMBL956549 | 0.83 | ALDH1A1 (0.42) | HDAC6HDAC1HDAC2L3MBTL1ALDH1A1 | |
| SCHEMBL12319215 | 0.83 | CA14 (0.33) | HDAC6CA14 | |
| SCHEMBL2411126 | 0.83 | CA14 (0.33) | HDAC6L3MBTL1CA14 | |
| SCHEMBL2754735 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1ALDH1A1 | |
| SCHEMBL17162509 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281109-B2 | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes | MERCK SHARP & DOHME LLC (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | Shanghai Pharmaceuticals Holding Cd., Ltd. (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20220177465-A1 | INHIBITORS OF HISTONE DEACETYLASE-3 USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATION DISEASES AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| EP-3677583-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| EP-3424928-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-5723607-A | Compounds useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMACETICALS, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0783507-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5641774-A | GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE INHIBITORS; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| US-5641771-A | FUSED AMIDINE-CONTAINING NITROGEN HETEROCYCLE COMPOUNDS AS ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| US-5639749-A | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5639747-A | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5625061-A | GRAFT=GLYCINAMIDE RIBONCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5610319-A | Compound useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5594139-A | FROM 5-HAL-2,6-DIAMINO-3H-4-OXOPYRIMIDINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996003407-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | ERBB2, EGFR, ERBB4 | HDAC6 1748/4885HDAC1 2674/4885HDAC2 2438/4885 |
| US-12281109-B2 | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885HDAC2 3/4885 |
| US-20220177465-A1 | INHIBITORS OF HISTONE DEACETYLASE-3 USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATION DISEASES AND DIABETES | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885HDAC2 3/4885 |
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | HDAC6 902/4885HDAC1 319/4885HDAC2 421/4885 |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | ERBB2, EGFR, ERBB4 | HDAC6 1774/4885HDAC1 2788/4885HDAC2 2462/4885 |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | HDAC6 1685/4885HDAC1 2517/4885HDAC2 1961/4885 |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | ERBB2, EGFR, ERBB4 | HDAC6 1685/4885HDAC1 2517/4885HDAC2 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.